Table 3.
Summary of disease recurrences
| Recurrence | Age, years | Surgery | PT | pN | Tumor size, cm | HG | LVI | RM | EPclin score | EPclin score class | RT field | CTx | ET | Time to recurrence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Local | 43 | BCS | 1c | 0 | 1.8 | I | No | (−) | 3.1 | Low risk | Breast only | No | TMX | 62 months |
| Local | 49 | BCS | 2 | 0 | 2.8 | II | No | (−) | 3.5 | High risk | Breast only | CMF #6 | TMX | 45 months |
| Local | 47 | BCS | 2 | 0 | 2.8 | II | No | Close | 3.6 | High risk | Breast only | CMF #6 | TMX | 13 months |
| Distant (bone) | 43 | BCS | 2 | 0 | 2.5 | II | No | (−) | 4.7 | High risk | Breast only | AC #4 | AI | 35 months |
| Distant (contralateral axilla, bone, liver) | 48 | BCS | 2 | 0 | 2.1 | II | No | Close | 4.2 | High risk | Breast only | AC #4 + weekly T #12 | TMX | 25 months |
| Distant (bone) | 54 | BCS | 2 | 0 | 2.1 | III | No | (−) | 4.2 | High risk | Breast only | TC #4 | TMX | 12 months |
HG, histologic grade; LVI, lymphovascular invasion; RM, resection margin; EP, EndoPredict; RT, radiotherapy; CTx, chemotherapy; ET, endocrine therapy; BCS, breast-conserving surgery; CMF, cyclophosphamide, methotrexate, fluorouracil; AC, adriamycin and cyclophosphamide; T, paclitaxel; TC, docetaxel and cyclophosphamide; TMX, tamoxifen; Al, aromatase inhibitor.